The company’s stock surges 236% on first data with its new EGFR project, so where’s the catch?
The anti-Ox40 ligand antibody amlitelimab could have its work cut out to best the company’s own Dupixent.
After a hiatus Nkarta comes back with a new lymphodepletion regimen to boost its lead Car-NK therapy.
Strong mid-stage data seem to show sonelokimab, a Merck KGaA cast-off, beating bigger rivals.
The private group celebrates a double first for its mRNA-generated Car-T therapy in myasthenia gravis.
Despite showing arguable signals of efficacy Uniqure’s Huntington’s disease gene therapy has some fundamental problems.